X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PF-06700841 (brepocitinib) is a novel small molecule TYK2/JAK1 inhibitor which is being evaluated for the treatment of patients with non-anterior non-infectious uveitis.
Lead Product(s): Brepocitinib
Therapeutic Area: Ophthalmology Product Name: PF-06700841
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2024
Details:
IMVT-1401 (batoclimab) is an FcRn inhibitor antibody drug candidate, which is currently being evaluated for the treatment of patients with Graves’ Disease.
Lead Product(s): Batoclimab
Therapeutic Area: Immunology Product Name: IMVT-1401
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
Through the acquisition, Roche will have full rights to develop and manufacture RVT-3101 (PF-06480605), a novel TL1A directed antibody for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, and commercialize it in the US and in Japan.
Lead Product(s): RVT-3101
Therapeutic Area: Gastroenterology Product Name: RVT-3101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $7,250.0 million Upfront Cash: $7,100.0 million
Deal Type: Acquisition December 14, 2023
Details:
PF-06700841 (brepocitinib) is a novel small molecule TYK2/JAK1 inhibitor which is being evaluated for the treatment of patients with systemic lupus erythematosus.
Lead Product(s): Brepocitinib
Therapeutic Area: Immunology Product Name: PF-06700841
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
Through the acquisition, Roche will have full rights to develop and manufacture RVT-3101 (PF-06480605), a novel TL1A directed antibody for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease, and commercialize it in the US and in Japan.
Lead Product(s): PF-06480605
Therapeutic Area: Gastroenterology Product Name: RVT-3101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $7,250.0 million Upfront Cash: $7,100.0 million
Deal Type: Acquisition October 23, 2023
Details:
RVT-3101, is a once monthly subcutaneously administered anti-TL1A antibody. RVT3101 has demonstrated best-in-indication potential treatment for Ulcerative Colitis (UC) and Crohn’s Disease.
Lead Product(s): PF-06480605
Therapeutic Area: Gastroenterology Product Name: RVT-3101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Details:
The net proceeds will be used to fund the development of RVT-3101. RVT-3101 is a phase 3-ready anti-TL1A antibody for Ulcerative Colitis, Crohn’s Disease and other indications.
Lead Product(s): RVT-3101
Therapeutic Area: Gastroenterology Product Name: RVT-3101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2023
Details:
RVT-3101 (PF-06480605), is a once monthly subcutaneously administered anti-TL1A antibody. RVT3101 has demonstrated best-in-indication potential treatment for Ulcerative Colitis (UC) and Crohn’s Disease.
Lead Product(s): PF-06480605
Therapeutic Area: Gastroenterology Product Name: RVT-3101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
RVT-3101 (PF-06480605) is a potential first-in-class agent that targets both inflammatory and fibrotic pathways by inhibiting TL1A, which has been shown to modulate the location and severity of inflammation and fibrosis by stimulating TH1 and TH17 pathways.
Lead Product(s): PF-06480605
Therapeutic Area: Gastroenterology Product Name: RVT-3101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
PF-06700841 (brepocitinib) is a potential first-in-class dual, selective inhibitor of TYK2 and JAK1; in all five placebo-controlled studies completed to date, oral brepocitinib generated statistically significant and clinically meaningful results.
Lead Product(s): Brepocitinib
Therapeutic Area: Immunology Product Name: PF-06700841
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
